MLKL and neoplasm: This could trigger a protective adaptive immune response, buy time for subsequent characterization of the tumor mutanome by exome sequencing and bio-informatic prediction tools, and subsequently boost the primed immune response induced by the MLKL-mRNA treatment with, for example, a follow-up therapeutic vaccination based on the identified neo-epitopes.